Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhib...

Full description

Bibliographic Details
Main Authors: Yumi Kambayashi, Kentaro Ohuchi, Hiromu Chiba, Erika Tamabuchi, Tasuku Nagasawa, Yoshihide Asano, Taku Fujimura
Format: Article
Language:English
Published: Karger Publishers 2022-05-01
Series:Case Reports in Oncology
Subjects:
tubulointerstitial nephritis
braf/mek inhibitor
adverse event
rheumatoid arthritis
melanoma
Online Access:https://www.karger.com/Article/FullText/524013

Internet

https://www.karger.com/Article/FullText/524013

Similar Items